FAQ: VolitionRx and Hologic Co-Marketing Agreement for Nu.Q® Discover Service
Summary
VolitionRx has signed a co-marketing and services agreement with Hologic to promote Volition's Nu.Q® Discover service, which offers epigenetic profiling assays for drug developers and scientists. This partnership represents a significant milestone that expands customer access to Volition's proprietary assays and strengthens their position in the pharmaco-epigenetics market.
What is the main purpose of the agreement between VolitionRx and Hologic?
The agreement establishes a co-marketing and services partnership where Hologic will promote Volition’s Nu.Q® Discover service, which offers a suite of assays for rapid epigenetic profiling across disease model development, preclinical testing, and clinical studies for drug developers and scientists.
Why is this agreement significant for VolitionRx?
This represents a significant milestone for Volition’s Nu.Q® Discover program that will greatly expand customer access to their proprietary assays, which have an estimated total addressable market of $200 million annually, and strengthens their position in the pharmaco-epigenetics market to help grow revenues.
What specific service is being promoted through this partnership?
The partnership focuses on promoting Volition’s Nu.Q® Discover service, which provides a suite of assays for rapid epigenetic profiling that can be used across disease model development, preclinical testing, and clinical studies by drug developers and scientists.
How long is the initial term of this agreement?
The initial term of the agreement is one year, with the potential to expand into an exclusive provider arrangement subject to further terms beyond the initial period.
What disease areas does Hologic have experience in that complement this partnership?
Hologic has extensive experience not only in oncology but also in cardiovascular, neurodegenerative, immunology and other disease areas where nucleosome quantification can provide additional valuable biological insights to biotech, pharma and academic clients.
What is VolitionRx’s overall mission and focus?
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Where can I find more information about VolitionRx?
For further information, visit the company’s website at www.Volition.com, though the contents found at Volition’s website are not incorporated by reference into this document.
What types of diseases is VolitionRx developing tests for?
Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
Where are VolitionRx’s research and development activities located?
Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London, making it a multi-national company with global operations.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 237511